SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001601830-23-000050
Filing Date
2023-07-12
Accepted
2023-07-12 08:32:33
Documents
15
Period of Report
2023-07-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rxrx-20230711.htm   iXBRL 8-K 36034
2 EX-10.1 ex101-rxrxnvidiastockpurch.htm EX-10.1 363237
3 EX-10.2 ex102-rxrxxnvidiaregrights.htm EX-10.2 136677
4 EX-99.1 ex991-rxrxxnvidiapr.htm EX-99.1 14040
  Complete submission text file 0001601830-23-000050.txt   768629

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rxrx-20230711.xsd EX-101.SCH 1907
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rxrx-20230711_lab.xml EX-101.LAB 24833
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rxrx-20230711_pre.xml EX-101.PRE 13047
9 EXTRACTED XBRL INSTANCE DOCUMENT rxrx-20230711_htm.xml XML 2746
Mailing Address 41S RIO GRANDE STREET SALT LAKE CITY UT 84101
Business Address 41S RIO GRANDE STREET SALT LAKE CITY UT 84101 (385) 269-0203
RECURSION PHARMACEUTICALS, INC. (Filer) CIK: 0001601830 (see all company filings)

IRS No.: 464099738 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40323 | Film No.: 231083308
SIC: 2836 Biological Products, (No Diagnostic Substances)